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Abstract
Background: MicroRNAs (miRNAs) are involved in cancer development and progression, acting as tumor
suppressors or oncogenes. Our previous studies have revealed that miR-148a and miR-152 are significantly down-
regulated in gastrointestinal cancers. Interestingly, miR-148b has the same “seed sequences” as miR-148a and miR-
152. Although aberrant expression of miR-148b has been observed in several types of cancer, its pathophysiologic
role and relevance to tumorigenesis are still largely unknown. The purpose of this study was to elucidate the
molecular mechanisms by which miR-148b acts as a tumor suppressor in gastric cancer.
Results: We showed significant down-regulation of miR-148b in 106 gastric cancer tissues and four gastric cancer
cell lines, compared with their non-tumor counterparts by real-time RT-PCR. In situ hybridization of ten cases
confirmed an overt decrease in the level of miR-148b in gastric cancer tissues. Moreover, the expression of miR-
148b was demonstrated to be associated with tumor size (P = 0.027) by a Mann-Whitney U test. We also found
that miR-148b could inhibit cell proliferation in vitro by MTT assay, growth curves and an anchorage-independent
growth assay in MGC-803, SGC-7901, BGC-823 and AGS cells. An experiment in nude mice revealed that miR-148b
could suppress tumorigenicity in vivo. Using a luciferase activity assay and western blot, CCKBR was identified as a
target of miR-148b in cells. Moreover, an obvious inverse correlation was observed between the expression of
CCKBR protein and miR-148b in 49 pairs of tissues (P = 0.002, Spearman’s correlation).
Conclusions: These findings provide important evidence that miR-148b targets CCKBR and is significant in
suppressing gastric cancer cell growth. Maybe miR-148b would become a potential biomarker and therapeutic
target against gastric cancer.
Introduction
Gastric cancer is the second leading cause of cancer-
related mortality worldwide [1]. As with other cancers,
the development of gastric cancer is a multistep process
with the accumulation of genetic and epigenetic
changes. Many molecular mechanisms have been
revealed, but the role of microRNAs (miRNAs) remains
to be elucidated in gastric cancer.
M i R N A sa r ear e c e n t l yd i s c o v e r e dc l a s so fn a t u r a l l y
occurring small non-coding RNAs involved in the regu-
lation of gene expression by targeting mRNAs for trans-
lational repression or cleavage [2,3]. Fifty percent of
miRNAs are located in the chromosomal regions known
to be frequently amplified or deleted in human cancer
cells [4]. Growing evidence indicates that these short
RNAs of 19 to 25 nucleotides play key roles in a wide
variety of biological processes including cell fate specifi-
cation, proliferation, cell death, and energy metabolism
[5-8]. Furthermore, an increasing number of miRNAs
have been shown to be involved in cancer development
and progression [9-13].
Our previous studies have revealed that miR-148a and
miR-152 are down-regulatedi ng a s t r o i n t e s t i n a l
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148b has the same “seed sequences” as miR-148a and
miR-152, however, its pathophysiologic role and rele-
vance to tumorigenesis are still largely unknown.
MiR-148b is located at chromosome 12q13 and recent
studies have found it is down-regulated in oral, pancrea-
tic, colon and gastric cancer tissues using microarray
analysis [15-18]. Moreover, some studies revealed that
m i R - 1 4 8 bm a yp l a yac r i t i c a lrole in osteogenesis [19]
and may influence the polymorphism of HLA-G [20].
Furthermore, Zhao et al. found miR-148b may play a
role in metastasis related to hepatocellular carcinoma
[21]. Interestingly, a recent study showed that the cod-
ing sequence of DNA methyltransferase 3b (Dnmt3b)
mediated regulation by the miR-148 family (miR-148a
and miR-148b) [22]. However, most studies addressing
the molecular mechanism of miR-148b in cellular trans-
formation and tumorigenesis are still in an early stage.
Thus, the identification of the function of miR-148b is
critical to understanding the role of miR-148b in cancer
development.
In this study, we analyzed miR-148b expression in
human gastric cancer tissues and their matched non-
tumor adjacent tissues by both qRT-PCR assay and
in situ hybridization. Further investigation revealed
that in gastric cancer cell lines, miR-148b functioned
as a tumor suppressor and overexpression of miR-
148b could inhibit cell proliferation in vitro and
in vivo. Subsequent experiments confirmed that the cho-
lecystokinin-B receptor (CCKBR) was a target of miR-
148b and was down-regulated by miR-148b at the
translational level. Our findings will help to elucidate the
functions of miRNAs and their roles in tumorigenesis.
Materials and methods
Human Tissue Samples
One hundred and six pairs of human gastric tissue sam-
ples were obtained from patients who underwent surgi-
cal resection at the First Hospital of China Medical
University between 2007 and 2008 and were diagnosed
with gastric cancer based on histopathological evalua-
tion. The matched non-tumor adjacent tissue was
obtained from a segment of the resected specimens that
was the farthest from the tumor (> 5 cm). The samples
were snap-frozen in liquid nitrogen and stored at -80°C.
No local or systemic treatment was conducted in these
patients before the operation. One section of each sam-
ple was stained with hematoxylin-eosin (H&E) and was
used for histopathological evaluation. The tumor histo-
logical grade was assessed according to World Health
Organization criteria and was staged using the TNM
staging of the International Union Against Cancer
(UICC)/American Joint Committee on Cancer (AJCC)
system (2002). The study was approved by the Research
Ethics Committee of China Medical University, China.
Informed consent was obtained from all patients.
Cell lines and culture conditions
Human gastric cancer cell lines MGC-803, BGC-823,
SGC-7901 and AGS and the normal gastric epithelium
cell line (GES-1) were purchased from the Institute of
Biochemistry and Cell Biology at the Chinese Academy
of Sciences (Shanghai, China). MGC-803, SGC-7901 and
BGC-823 were cultured in RPMI 1640 medium (Invitro-
gen). AGS was cultured in F12 medium (Invitrogen).
GES-1 was cultured in Dulbecco’s Modified Eagle med-
ium (Invitrogen). They were all supplemented with 10%
fetal boving serum (Invitrogen) at 37°C and 5% CO2.
RNA isolation and real-time RT-PCR
Total RNA from the specimens and cultured cells, with
efficient recovery of small RNAs, was isolated using the
miRVana RNA isolation kit according to the manufac-
turer’s instructions (Ambion). Poly(A) tail was added to
the RNA using a Poly(A) Tailing Kit according to the
manufacturer’s instructions (Ambion). The first-strand
cDNA was synthesized using the SuperScript
® III First-
Strand Synthesis System according to the manufacturer’s
instructions (Invitrogen). Quantitative PCR was done
using EXPRESS SYBR
® GreenER™ qPCR Supermix Uni-
versal (Invitrogen) and was performed in a Real-time
PCR System Rotor-Gene 6000 (Qiagen). The expression
of miRNAs was calculated relative to U6 small nuclear
R N A .C h a n g e si ne x p r e s s i o nw ere calculated using the
ΔΔCt method [23]. The relative expression ratio of miR-
148b was presented as the fold change normalized to an
endogenous reference (U6 RNA) and relative to the
nontumorous controls (normal tissues and normal cell
line). Therefore, the value of the relative expression
ratio <1.0 was considered as low expression in cancer
relative to the nontumorous control and the ratio >1.0
was considered as high expression. Primers used for RT-
PCR are indicated in Additional file 1 Table S1.
In situ hybridization
In situ detection of miR-148b was performed on paraffin
sections using a DIG-labeled miRCURY™ Detection
probe according to the manufacturer’s instructions (Exi-
qon). Ten cases of gastric cancer were selected. The sec-
tions were deparaffinized and deproteinated, which was
followed by prehybridization, hybridization [hybridiza-
tion temperature = Tm probe - 21°C], stringency wash-
ing and immunological detection. The sections were
then exposed to a streptavidin-peroxidase reaction sys-
tem and developed with 3,3’-diaminobenzidine (DAB).
Slides were counterstained with hematoxylin and ana-
lyzed with a Nikon 80i microscope and Nikon NIS-
Elements F 2.3 software (Nikon).
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MiR-148b mimics was a RNA duplex (Additional file 1,
Table S2) designed as described previously [24]. The nega-
tive control (NC) RNA duplex (Additional file 1, Table S2)
was nonhomologous to any human genome sequences.
For growth curves, an anchorage-independent growth
assay in vitro and tumorigenicity assay in vivo, all pyrimi-
dine nucleotides in the miR-148b or NC duplex were sub-
stituted by their 2-O-methyl analogues to improve RNA
stability. The anti-miR-148b, with sequence of 5’-ACAAA
GUUCUGUGAUGCACUGA-3’,w a sa2 ’-O-methyl-
modified oligoribonucleotide designed as an inhibitor of
miR-148b. The anti-NC, with a sequence of 5’-CAGUA
CUUUUGUGUAGUACAA-3’, was used as a negative
control for anti-miR-148b in the antagonism experiment.
T h es p e c i f i cs i R N As e q u e n c e5 ’-AAGCGCGTGGTGC
GAATGTTG-3’ resides in exon 5 of the human CCKBR
gene (Genbank accession no. NM_176875). The control
siRNA sequence, 5’-AAGCTTCATAAGGCGCATAGC-3’
is located on chromosome 11 of the mouse and has no
homology with the human genome by BLAST compari-
son. All the RNA oligoribonucleotides were purchased
from Genepharma (Shanghai, China).
Transfection was performed with lipofectamine 2000
Reagent (Invitrogen) following the manufacturer’s proto-
col. A final concentration of 50 nM of RNA mimics or
200 nM of inhibitor or 100 nM of siRNA and their
respective negative controls were used for each transfec-
tion in proliferation, cell cycle, apoptosis and animal
experiments. Moreover, a blank control was set up for
each transfection without plasmids. Transfection effi-
ciency was monitored by qRT-PCR or western blot.
Cell proliferation assay
MTT proliferation assay
The capacity for cellular proliferation was measured with a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay. Twenty-four hours after RNA transfec-
tion, cells (approximately 8 × 10
3) were seeded into
96-well culture plates for 24 h, 48 h, 72 h and 96 h. The
cells were then incubated with 20 μL of MTT (5 mg/mL)
for 4 h at 37°C and 150 μL of DMSO was added to solubi-
lize the crystals for 20 min at room temperature. The opti-
cal density was determined with a spectrophotometer
(Multiskan MK3 [Thermo]) at a wavelength of 490 nm.
Growth curves
Twenty-four hours after RNA transfection, equal num-
bers (approximately 4 × 10
4) of cells were seeded into
six-well plates. The cells were harvested and counted by
trypan blue exclusion method every day after seeding.
Anchorage-independent growth assay
Twenty-four hours after RNA transfection, SGC-7901
cells (2 × 10
2) were suspended in 2 mL of 0.3% agarose
with RPMI 1640 medium containing 10% FBS and pla-
ted into six-well plates on top of an existing layer of
0.6% agarose prepared with the same medium. The
plates were incubated at 37°C in a 5% CO2 incubator.
After four weeks, cell colonies were fixed with methanol
and stained with 0.1% crystal violet for 10 min. Then,
the colonies were captured with Olympus SZX12 and
Qcapture Pro software (Olympus). Cell colonies >0.1
mm in diameter were counted under a microscope.
Cell cycle analysis
For cell cycle analysis, 48 h after transfection, the
adhered cells were obtained by trypsinization and pooled
with the floating cells and centrifuged at 1000 rpm for
5 min. Propidium iodide (0.05 mg/ml, Sigma) and RNA-
seA (0.1 mg/ml, Sigma) were added to the cells and
samples were analyzed 30 min after staining with the
use of flow cytometry -BD FACSCalibur (BD) and Cell-
Quest software.
Apoptosis assay
For apoptosis assays, floating and adherent cells were
harvested 24 h or 48 h after transfection, and then com-
bined and washed with PBS. Annexin-V in combination
with propidium iodide (KeyGen) was added to the cells
and samples were analyzed within 30 min after staining.
Quantification of fluorescence was done by flow cyto-
metry as described above.
Tumorigenicity assays in nude mice
Six-week-old female BALB/c athymic nude mice were
subcutaneously injected in the right armpit region with
1.5 × 10
6 cells in 0.15 mL of PBS. Three groups of mice
(n = 11) were tested. Group 1 (miR-148b mimics) was
injected with MGC-803 cells transfected with miR-148b
mimics; group 2 (NC) was injected with MGC-803 cells
transfected with NC; and group 3 (MGC-803) was
injected with MGC-803 cells alone. The tumor size was
measured every 2 or 3 days with calipers. The tumor
volume was calculated with the formula: (L × W
2)/2,
where L is the length and W is the width of the tumor.
After the mice were killed at four weeks, the weights of
the tumors were measured. All experimental procedures
involving animals were in accordance with the Guide for
the Care and Use of Laboratory Animals (NIH publica-
tion no. 80-23, revised 1996) and were performed
according to the institutional ethical guidelines for ani-
mal experiments.
Bioinformatics method
The miRNA targets predicted by computer-aided algo-
rithms were obtained from PicTar (http://pictar.mdc-
berlin.de/ [25]), TargetScan (http://www.targetscan.org
[26]) and miRBase Targets (http://www.mirbase.org/
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studied by Expression Analysis Systematic Explorer
(EASE) analysis based on the Gene ontology database
and KEGG pathway database [28].
Vector construction
Luciferase reporters were generated based on the firefly
luciferase expressing vector pGL3-control (Promega). To
construct pGL3-CCKBR-3’UTR, a partial 3’UTR of the
CCKBR segment of human CCKBR mRNA (1568-2044
nt, Genbank accession no. NM_176875) containing the
putative miR-148b binding sites was amplified and
cloned into the vector pGL3-control. We then used the
same method to construct pGL3-DNMT1-3’UTR (5080-
5399 nt, Genbank accession no. NM_001130823), pGL3-
WNT10B-3’UTR (1574-1844 nt, Genbank accession
no. NM_003394), pGL3-NOG-3’UTR (1299-1457 nt,
Genbank accession no. NM_005450) and pGL3-
ROBO1-3’UTR (5903-6340 nt, Genbank accession no.
NM_002941). We constructed another two luciferase
reporters. One was pGL3-CCKBR-3’UTR-conserved,
which contains a putative miR-148b binding site in a
conserved region of 3’UTR (1904-2044 nt). The other
was pGL3-CCKBR-3’UTR-poorly conserved, which con-
tains a putative miR-148b binding site in a poorly con-
served region of 3’UTR (1568-1753 nt). In addition, we
also constructed a luciferase reporter that had a com-
plete complementary sequence to miR-148b as a positive
control (PC). Primers used for vector construction are
indicated in Additional file 1 Table S3.
Luciferase activity assay
Cells were seeded in 24-well plates at 5 × 10
4 cells per
well the day before transfection. 400 ng of luciferase
reporter, 40 pmol (miR-148b mimics or NC) and 40 ng
of pRL-TK were added in every well. Cells were col-
lected 48 h after transfection and analyzed using the
Dual-Luciferase Reporter Assay System (Promega) and
Centro LB 960 (Berthold).
Protein extraction and western blot
Total protein from the specimens and cultured cells was
extracted using the total protein extraction kit according
to the manufacturer’s instructions (KeyGen). Proteins
were separated by 8% SDS polyacrylamide gels and elec-
trophoretically transferred to polyvinylidene difluoride
membranes (Millipore). Membranes were blocked in 5%
non-fat milk in TBS with 0.05% Tween-20 (TBST) at
room temperature for 1 h. Antibodies directed against
CCKBR (1:200, Abcam) and b-actin (1:5000, Sigma)
were used. The proteins were visualized with an ECL kit
(Pierce) and MF-Chemi BIS 3.2 Pro (Micro Photonics)
with GelCapture Version software. The intensity of pro-
tein fragments was quantified using FluorChem 2.01
software (Alpha Innotech). CCKBR protein levels in can-
cer tissues were presented as fold change normalized to
an endogenous reference (b-actin protein) and relative
to the matched non-tumor adjacent tissues. Therefore,
the fold change of CCKBR protein <1.0 was considered
as low expression, whereas the fold change of CCKBR
protein >1.0 was regarded as high expression.
Statistical analysis
Data are presented as mean ± SD from at least three
separate experiments. Statistical analysis was performed
with Student’s t-test, non-parametric test (Mann-
Whitney U test between 2 groups and Kruskall-Wallis
test for 3 or more groups). The statistical significance of
correlations between the expression of miR-148b and
CCKBR protein were calculated by a chi-square test and
Spearman’s rank correlation. Statistical analysis was
performed using SPSS 16.0 computer software. Differ-
ences were considered statistically significant at P < 0.05.
Results
Expression of miR-148b and its correlation with
clinicopathological characteristics of gastric cancer
Using a qRT-PCR method, miR-148b was detected in all
106 (100%) pairs of gastric cancer tissues and their
matched non-tumor adjacent tissues, as well as the gas-
tric cell lines. Among 106 patients with gastric cancer,
66 of 106 (62.26%) cases revealed >50% reduction in the
miR-148b level relative to their matched non-tumor
adjacent tissues (Figure 1A). In cell lines, we investigated
the expression level of miR-148b in gastric cancer cell
lines (MGC-803, SGC-7901, BGC-823 and AGS) relative
to the normal gastric epithelial cell line (GES-1). Com-
pared with GES-1, miR-148b was down-regulated with
different expression levels in MGC-803 (0.21 ± 0.04-
fold), SGC-7901 (0.34 ± 0.15-fold), BGC-823 (0.55 ±
0.21-fold) and AGS (0.79 ± 0.14-fold; Figure 1B).
Furthermore, with in situ hybridization of ten cases,
miR-148b was detected both in the normal epithelial
cells and in the carcinoma cells (Figure 1C). Results
confirmed an overt decrease in the level of miR-148b
compared to their matched non-tumor adjacent tissues
(Figure 1C and Additional file 2, Figure S1).
We then studied the correlation between miR-148b
expression and clinicopathological characteristics of gas-
tric cancer. The Mann-Whitney U test revealed that the
expression levels of miR-148b were associated with
tumor size (P = 0.027) in gastric cancer patients
(Table 1). The patients with low expression of miR-148b
tended to have larger tumor sizes (≥6 cm).
MiR-148b inhibits cell proliferation in vitro
The significant reduction of miR-148b expression in
gastric cancer samples prompted us to explore the
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genesis. As an initial step, we detected expression of
miR-148b by qRT-PCR 48 h after transfection of miR-
148b mimics, anti-miR-148b, their respective NCs and
blank controls (MGC-803). Transfection efficiency was
perfect (Additional file 2 Figure S2).
According to the results of the MTT assay and growth
curves, we found that the cells (MGC-803, SGC-7901 and
BGC-823), which were transiently transfected with miR-
148b mimics, had a significant growth inhibition at differ-
ent degrees (Figure 2A, B). To provide further evidence
that miR-148b was indeed involved in gastric cancer cell
growth, we studied the effect of the inhibitor of miR-148b
in AGS cells. Proliferation of the cells transfected with anti-
miR-148b was increased compared with that of the cells
transfected with anti-NC and blank controls (Figure 2C).
To determine whether the inhibition of growth induced
by miR-148b in cells was anchorage-independent, the
cells were plated on soft agar 24 h after RNA transfection
in SGC-7901 cells. After four weeks, the cells transfected
with miR-148b mimics formed significantly fewer colo-
nies on soft agar than cells transfected with NC and the
blank control (Figure 2D). To further examine whether
the decrease in proliferation of MGC-803, SGC-7901 and
BGC-823 cells reflected a cell cycle arrest, cell cycle pro-
gression was analyzed by propidium iodide staining and
flow cytometer analysis. The results revealed that MGC-
803 and SGC-7901 cells transfected with miR-148b
mimics had an obvious cell cycle arrest at the S-G2/M
phase (Figure 2E). However, we did not get a similar
result in BGC-823 cells. On the other hand, the apoptosis
assay revealed that miR-148b had no effect on apoptosis
in MGC-803 cells (Additional file 2, Figure S3).
MiR-148b suppresses tumorigenicity in vivo
To confirm the above findings, an in vivo tumor model
was used. MiR-148b mimics-transfected MGC-803 cells
(miR-148b mimics), NC-transfected MGC-803 cells (NC)
and MGC-803 cells were injected separately into three
groups of nude mice (n = 11). Four weeks after injection,
the group with miR-148b mimics had a lower mortality
rate (9.09%) and formed substantially smaller tumors
than the other 2 groups (Figure 3A). The tumor volume
at the time of death in mice injected with miR-148b
mimics-transfected cells was 60.49 ± 53.29 mm
3, whereas
the tumor volume of mice injected with NC or MGC-803
cells were 140.81 ± 72.21 mm
3 and 180.43 ± 127.89 mm
3,
respectively (Figure 3B). Moreover, the mean tumor
weight at the end of the experiment was markedly lower
in the group with miR-148b mimics (0.063 ± 0.068 g)
compared to the NC and MGC-803 groups (0.162 ±
0.106 g and 0.17 ± 0.091 g; Figure 3C, D).
Figure 1 The expression of miR-148b in tissues and cell lines. (A), MiR-148b was detected in 106 gastric cancer patients by qRT-PCR. Data
were presented as log2 of fold change of gastric cancer relative to non-tumor adjacent tissues. The cases below the line (log2 = -1) revealed
>50% reduction in the miR-148b level. (B), The relative level of miR-148b in gastric cancer cell lines (MGC-803, SGC-7901, BGC-823, AGS) relative
to normal gastric epithelial cell line (GES-1). (C), H & E staining and detection of miR-148b by in situ hybridization in serial sections from gastric
cancer tissue and its matched non-tumor adjacent tissue. Images are overlay images with brown color representing miR-148b expression. Data
are presented as mean ± SD from at least three separate experiments. *, P < 0.05; **, P < 0.01.
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SGC-7901 and BGC-823 cells using a luciferase activity
assay
Many putative miR-148b targets are predicted by var-
ious computer-aided algorithms. After Expression Ana-
lysis Systematic Explorer (EASE) analysis, eleven genes
were picked out as candidate targets of miR-148b
(Additional file 1 Table S4). Among the possible candi-
dates, we further analyzed DNMT1, CCKBR, WNT10B,
NOG and ROBO1, which are five genes whose functions
have been associated with carcinogenesis or cancer
development. Interestingly, the relative luciferase activity
of these reporters was suppressed at different degrees
when miR-148b mimics was cotransfected in MGC-803
cells compared with the NC (Figure 4A). However, we
found that the relative luciferase activity of the pGL3-
CCKBR-3’UTR reporter was significantly suppressed.
These results indicate that CCKBR may be a target of
miR-148b.
Then, we found that the 3’-UTR of CCKBR has two pre-
sumed sites in the conserved and poorly conserved regions
that can bind with the seed region of miR-148b.
So we constructed another two luciferase plasmids,
pGL3-CCKBR- 3’UTR-conserved and pGL3-CCKBR-
3’UTR-poorly conserved. Furthermore, we analyzed these
luciferase reporters in MGC-803, SGC-7901 and BGC-823
cells. The results revealed that the relative luciferase activ-
ity of the pGL3-CCKBR-3’UTR reporter was obviously
suppressed by miR-148b mimics in these cells but pGL3-
CCKBR-3’UTR-conserved or pGL3-CCKBR-3’UTR-poorly
conserved had no overt variation (Figure 4B).
The inverse correlation between the expression of miR-
148b and CCKBR protein in cells and tissue samples
To confirm CCKBR is a target of miR-148b, we trans-
fected MGC-803 cells with miR-148b mimics and the
NC. Forty-eight hours after transfection, we examined
the CCKBR protein levels in cells by western blot.
Obviously, CCKBR protein levels were suppressed by
miR-148b mimics in MGC-803 cells (Figure 4C).
Despite the effect of miR-148b on CCKBR protein
l e v e l s ,n oe f f e c to nt h eC C K B Rm R N Al e v e lw a s
detected by qRT-PCR (Figure 4D).
In addition, we measured CCKBR protein levels in 49
pairs of the previously studied 106 gastric cancer tissues
and their matched non-tumor adjacent tissues, which
had already been verified as expressing miR-148b by
qRT-PCR. After we quantified the protein fragments, an
obvious inverse correlation was observed between the
expression of CCKBR and miR-148b in tissue samples
(P = 0.002, Table 2). Nevertheless, the correlation coeffi-
cient was not perfect (r = -0.436).
Effects of knockdown of the CCKBR gene on cell
proliferation in MGC-803 cells
The results above showed that miR-148b could inhibit
cell proliferation in vitro and suppress tumorigenicity in
vivo. Moreover, CCKBR is a potential target of miR-
148b using a luciferase activity assay. Therefore, we
asked whether CCKBR has an effect on gastric cancer
Table 1 Associations between the expression of
miR-148b with clinicopathological features in 106
patients with gastric cancer
n miR-148b
a
Sex
Male 80 0.28(0.08-1.26)
Female 26 0.47(0.25-1.24)
P 0.272
Age (years)
≤65 65 0.41(0.10-1.24)
> 65 41 0.27(0.08-1.26)
P 0.500
Tumor size (cm)
< 6 73 0.46(0.13-1.47)
≥6 33 0.23(0.05-0.43)
P 0.027*
Macroscopic type
Early stage 3 1.82(1.67-1.85)
Borrmann I+II 9 0.50(0.26-1.01)
Borrmann III+IV 94 0.31(0.08-1.16)
P 0.098
Histologic grade
Good 23 0.31(0.10-0.61)
Poor 83 0.41(0.08-1.28)
P 0.626
pT stage
T1+T2 51 0.39(0.09-1.27)
T3+T4 55 0.36(0.08-1.23)
P 0. 985
pN stage
N0 25 0.28(0.08-0.69)
N1 34 0.39(0.08-0.94)
N2 29 0.47(0.20-1.70)
N3 18 0.17(0.05-0.64)
P 0.171
pTNM stage
I 20 0.35(0.09-0.66)
II 22 0.33(0.08-0.94)
III 39 0.43(0.17-1.27)
IV 25 0.27(0.06-3.13)
P 0.821
Invasion into lymphatic vessels
Negative 77 0.41(0.10-1.30)
Positive 29 0.27(0.06-1.00)
P 0.346
a Median of relative expression, with 25th-75th percentile in parenthesis.
*Indicated statistical significance (P < 0.05).
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Page 6 of 13Figure 2 MiR-148b inhibits cell proliferation in vitro. (A), MTT proliferation assay in MGC-803, SGC-7901 and BGC-823. (B), Growth curves by
counting cell number in MGC-803, SGC-7901 and BGC-823. (C), MTT proliferation assay in AGS. (D), Anchorage-independent growth assay in
SGC-7901 cells. The colonies were counted (top) and captured (bottom). (E), The results of cell cycle analysis in MGC-803 and SGC-7901 cells. All
results were reproducible in three independent experiments. *, P < 0.05; **, P < 0.01.
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gene was knocked down by transfection of MGC-803
cells with siRNA (Additional file 2 Figure S4). A MTT
proliferation assay showed that knockdown of CCKBR
gene expression significantly inhibited cell proliferation
(Figure 4E).
Discussion
Until now, miRNA expression was studied by microar-
rays [29], bead-based flow cytometric assay [30],
northern blot [31], real-time PCR [32], in situ hybridiza-
tion [33], modified Invader assay [34] and other techni-
ques. However, real-time PCR has an advantage in that
i ti sam o r eq u a n t i t a t i v ea n dm o r es e n s i t i v em e t h o d
compared with other high-throughput assays. Moreover,
although altered expression levels of many miRNAs
have been identified in human cancers [35], few studies
have described miRNA expression associated with clini-
copathological characteristics in gastric cancer. There-
fore, we used real-time PCR and in situ hybridization to
Figure 3 MiR-148b suppresses tumorigenicity in vivo. Three groups of mice (n = 11) were tested. (A) , the number of alive mice and the
size of tumors in three groups. (B), the tumor growth curves of three groups during four weeks. (C), Each tumor lump was removed from the
body, and three mice with miR-148b mimics didn’t form any tumors. (D), the mean tumor weight of three groups at the end of the experiment.
Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01.
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Page 8 of 13Figure 4 CCKBR is a potential target of miR-148b in SGC-7901, MGC-803, BGC-823 cells. (A), analysis of luciferase activity of five possible
target genes with miR-148b mimics or NC in MGC-803 cells. (B), analysis of luciferase activity of pGL3-CCKBR-3’UTR, pGL3-CCKBR-3’UTR-poorly
conserved, pGL3-CCKBR-3’UTR-conserved and positive control (PC) with miR-148b mimics or NC in MGC-803, SGC-7901 and BGC-823 cells. (C&D),
Western blot and qRT-PCR were used to monitor the expression level of CCKBR in MGC-803 cells 48 h after transfection with miR-148b mimics
or NC. (E), Effects of knockdown of the CCKBR gene on cell proliferation in MGC-803 cells.
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Page 9 of 13profile the expression of miR-148b in a large number of
cases and clarified the relationship between miR-148b
and clinicopathological characteristics in gastric cancer.
In our study, we found significant low-expression of
miR-148b in gastric cancer tissues and cell lines. Ueda
et al. also found this tendency in gastric cancer tissues
by microarray analysis [18]. Taken together, these
results suggest that reduced miR-148b is a frequent
event in human gastric cancer tissues and may be
involved in carcinogenesis as a tumor suppressor gene.
Nevertheless, although down-regulation of miR-148b
was detected in some cancers, only Zhao et al. found
miR-148b may have a relationship with metastasis in
hepatocellular carcinoma [21]. However, in the present
study, miR-148b expression was found to be associated
with tumor size (P = 0.027) in gastric cancer patients.
The patients with low expression of miR-148b tended to
have larger tumor sizes (≥6 cm). Moreover, tumor size
has been considered as an important prognostic factor
for gastric cancer patients [36]. In view of the above, we
speculate that miR-148b may participate in gastric can-
cer progression.
Deregulated cell proliferation is a key mechanism for
neoplastic progression [37]. Our MTT assay and growth
curves results both indicate that miR-148b is associated
with significant growth inhibition in gastric cancer cells
at different degrees. This was further supported by the
finding that the overexpression of miR-148b could inhi-
bit tumor formation and growth in nude mice. More-
over, these findings also confirm the previous result of
qRT-PCR. On the other hand, what is responsible for
miR-148b induced inhibition of proliferation? Generally,
cell cycle arrest is an important factor [38,39]. Indeed,
our subsequent cell cycle analysis revealed that MGC-
803 and SGC-7901 cells transfected with miR-148b
mimics had an obvious cell cycle arrest at the S-G2/M
phase. Nevertheless, we did not get a similar result in
BGC-823 cells. Bandi et al. documented that cell cycle
arrest induced by miR-15a and miR-16 depended on the
expression of Rb [9]. Possibly the process of cell cycle
arrest induced by miR-148b is influenced by another
molecular mechanism as indirect regulation. This also
indicates that miR-148b may play different roles in
different cells.
The fundamental function of miRNA is to regulate
targets by direct cleavage of the mRNA or by inhibition
of protein synthesis, according to the degree of comple-
mentarities with the 3’UTR of targets. Perfect or nearly
perfect base pairing induces target mRNA cleavage,
whereas imperfect base pairing induces mainly transla-
tional silencing of the target [40]. The bioinformatics
analysis has estimated that as many as 30% of human
genes are miRNA targets [41]. In the present study, one
of our predicted target genes is CCKBR. Moreover, we
used a luciferase activity assay and western blot to con-
firm that CCKBR is a target of miR-148b in cells. And
subsequently, an obvious inverse correlation was
observed between the expression of CCKBR and miR-
148b in 49 pairs of tissue samples. However, miR-148b
has no effect on the CCKBR mRNA level detected by
qRT-PCR. These results highlight that miR-148b inter-
acts with CCKBR and negatively regulates its expression
at the translational level.
CCKBR is widely distributed throughout the human
gastrointestinal tract, pancreas, lung and some neuroen-
docrine tissues. The main function is to mediate the
normal physiological function of gastrin. Gastrin acts as
a potent cell-growth factor and has proliferative effects
on various malignancies including gastric, colorectal,
pancreatic, medullary thyroid cancers and small cell
lung cancer, as well as tumors of the central and periph-
eral nervous systems through CCKBR [42-47]. In the
present study, we found that knockdown of CCKBR
gene expression significantly inhibited MGC-803 cell
proliferation. Moreover, a recent study also found that
disrupting the gastrin-CCKBR autocrine loop by neutra-
lizing the endogenous gastrin or by knocking down
CCKBR expression significantly inhibited cell prolifera-
tion in SGC-7901 cells [48]. Therefore, we propose that
miR-148b may have an effect on proliferation in gastric
cancer, depending on regulating the expression of
CCKBR. Interestingly, luciferase reporters, pGL3-
CCKBR-3’UTR-conserved and pGL3-CCKBR-3’UTR-
poorly conserved, which have presumed sites, did not
show a significant correlation with miR-148b. Possibly,
miR-148b regulates the expression of CCKBR depending
on other binding sites or three-dimensional reconstruc-
tions of 3’UTR. Furthermore, although we found an
obvious inverse correlation between the expression of
CCKBR and miR-148b in tissue samples, the correlation
coefficient was not perfect (r = -0.436). It is worth con-
sidering whether there are other mechanisms involved
in the regulation processes of miR-148b.
Lars et al. documented a direct link between miR-129
and 2 putative targets GALNT1 and SOX4 by luciferase
activity assay in HEK293 cells [11]. The miR-15a and
Table 2 Correlation between the expression of miR-148b
and CCKBR protein in 49 gastric cancer cases
miR-148b
a Spearman’s correlation
low high n p p r
CCKBR
b
low 8 6 49 0.002 0.002 -0.436
high 34 1
aNumber of cancers with reduced or increased levels of miR-148b relative to
non-tumor adjacent tissues.
bNumber of cancers with reduced or increased levels of CCKBR protein
relative to non-tumor adjacent tissues.
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than one target [9,10,49]. Moreover, miR-101 regulated
the expression of Mcl-1 in liver cancer cells and regu-
lated cyclooxygenase-2 in colon cancer cells [12,50].
Duursma et al. studied the target of miR-148 in the pro-
tein coding region and found that human miR-148
represses the expression of the DNA methyltransferase
3b (Dnmt3b) gene, which is the primary mediator of
establishment and maintenance of DNA methylation in
mammals [22]. Therefore, miR-148b may regulate differ-
ent targets in the same cells, in different cells or
depending on different binding regions. Moreover,
although CCKBR can be regulated by miR-148b, an
indirect mechanism cannot be excluded.
The 2 nt - 8 nt of miRNA, known as the “seed
region”, has been suggested to be the most important
recognition site [51]. As shown on the miRbase website,
miR-148a, miR-148b and miR-152 have the same “seed
sequences”. Linsley et al. reported that, in a colon carci-
noma cell line, the microRNA-16 family could regulate
different targets in a coordinated fashion, including
CDK6, CARD10, CDC27 and C10orf46, which act in
cell cycle progression [49]. Braun et al. studied miR-192
and miR-215, which have the same “seed sequences”,
and showed they can both act as effectors as well as reg-
ulators of p53 [52]. Moreover, Katada et al. and our pre-
vious work studied the expression of miR-148a and
miR-152 in gastric cancer tissues and found they were
down-regulated compared with non-tumor adjacent tis-
sues [53,14]. We also found CCKBR was a putative tar-
get of miR-148a and miR-152 previously [14]. Therefore,
miR-148a, miR-148b and miR-152 may play the same
role in gastric cancer by regulating the same targets, and
the relationship among them need further investigation.
In conclusion, we showed there was significant low-
expression of miR-148b in gastric cancer tissues and cell
lines compared with their non-tumor counterparts.
Moreover, the expression of miR-148b was found to be
associated with tumor size in gastric cancer patients.
Our data also suggest that miR-148b can inhibit cell
proliferation in vitro and in vivo. Maybe miR-148b
would become a potential biomarker and therapeutic
target against gastric cancer. However, the regulation
processes of miR-148b, as well as the relationship
between miR-148a, miR-148b and miR-152, need further
study.
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Additional file 1: Supplementary tables. Table S1: RT-PCR primers for
amplification of miR-148b. Table S2: The sequence of hsa-miR-148b
mimics and negative control(NC), anti-miR-148b and anti-NC, siRNA and
NC for CCKBR. Table S3: Primers used for luciferase reporters
construction. Table S4: Putative target genes of miR-148b.
Additional file 2: Supplementary figures. Figure S1: An overt
decrease in the level of miR-148b in ten gastric cancer tissues
compared to their matched non-tumor adjacent tissues. In situ
detection of miR-148b was performed on paraffin sections using DIG-
labeled miRCURY™ Detection probe according to the manufacture’s
instructions (Exiqon). Images were overlay images with brown color
representing miR-148b expression. Obviously, most of the cases revealed
a significant decrease in the level of miR-148b in gastric cancer tissues
compared to their matched non-tumor adjacent tissues. Figure S2:
Transfection efficiency of miR-148b mimics or anti-miR-148b and
their respective NCs and blank controls. 48 h after transfection, the
efficiency of transfection with miR-148b mimics or anti-miR-148b was
monitored by qRT-PCR. A, The relative expression of miR-148b which was
transfected with miR-148b mimics was very high (476.33 ± 52.97-fold,
compared with NC). B, The relative expression of miR-148b which was
transfected with anti-miR-148b was significantly low (0.66 ± 0.55-fold,
compared with anti-NC). Figure S3: Apoptosis assay in MGC-803 cells.
For apoptosis assays, floating and adherent cells were harvested 24 h or
48 h after transfection, and then combined and washed with PBS.
Annexin-V in combination with propidium iodide (KeyGen) was added to
the cells and samples were analyzed within 30 min after staining. The
apoptosis assay revealed that miR-148b had no effect on apoptosis in
MGC-803 cells. Figure S4: Transfection efficiency of siRNA and NC for
CCKBR. 48 h after transfection, the efficiency of transfection was
monitored by qRT-PCR (A) and western blot (B).
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